News >

Novel Agents Move Through Relapsed/Refractory Myeloma Pipeline

Ellie Leick
Published: Monday, Feb 10, 2020

Shebli Atrash, MD, a physician in hematology and medical oncology at Levine Cancer Institute at Atrium Health

Shebli Atrash, MD

With more novel therapies moving through the pipeline, such as selinexor (Xpovio) and belantamab mafodotin, researchers continue to evaluate the patient populations in which these drugs perform best, explained Shebli Atrash, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication